Back to top
more

Fate Therapeutics (FATE)

(Real Time Quote from BATS)

$1.03 USD

1.03
498,844

-0.05 (-4.63%)

Updated Aug 6, 2025 02:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Top Cancer Stocks to Supercharge Your 2025 Portfolio

by Kinjel Shah

Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.

Zacks Equity Research

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

by Zacks Equity Research

FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.

Zacks Equity Research

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 17.95% and 222.57%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

by Zacks Equity Research

The FDA bestows a Regenerative Medicine Advanced Therapy tag on FATE's pipeline candidate, FT819, for treating moderate-to-severe systemic lupus erythematosus.

Zacks Equity Research

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

by Zacks Equity Research

FATE Therapeutics' Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.

Zacks Equity Research

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.55% and 46.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

by Zacks Equity Research

IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

by Zacks Equity Research

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

Zacks Equity Research

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.

Zacks Equity Research

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 4.76% and 249.32%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

by Zacks Equity Research

Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.

Zacks Equity Research

Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

by Zacks Equity Research

ALKS reports weaker-than-expected third-quarter 2024 results. Net sales of proprietary products increase year over year. Shares down.

Zacks Equity Research

VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements

by Zacks Equity Research

Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.

Zacks Equity Research

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

by Zacks Equity Research

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

Zacks Equity Research

NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients

by Zacks Equity Research

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients compared to placebo.

Zacks Equity Research

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy

by Zacks Equity Research

Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

by Zacks Equity Research

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.